Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

Inhibitors of the mutant isocitrate dehydrogenase 1 (IDH1) entered recently in clinical trials for glioma treatment. Mutant IDH1 produces high levels of 2-hydroxyglurate (2HG), thought to initiate oncogenesis through epigenetic modifications of gene expression. In this study, we show the initial evi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Commun
Autors principals: Andronesi, Ovidiu C., Arrillaga-Romany, Isabel C., Ly, K. Ina, Bogner, Wolfgang, Ratai, Eva M., Reitz, Kara, Iafrate, A. John, Dietrich, Jorg, Gerstner, Elizabeth R., Chi, Andrew S., Rosen, Bruce R., Wen, Patrick Y., Cahill, Daniel P., Batchelor, Tracy T.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5902553/
https://ncbi.nlm.nih.gov/pubmed/29662077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-03905-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars